The Technical Analyst
Galmed Pharmaceuticals [GLMD]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Galmed Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.63% $0.361
America/New_York / 23 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1.376 mill |
| EPS: | -2.50 |
| P/E: | -0.140 |
| Earnings Date: | May 30, 2024 |
| SharesOutstanding: | 3.81 mill |
| Avg Daily Volume: | 0.213 mill |
| RATING 2024-04-23 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Sell | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | ||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.140 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.02x |
| Company: PE -0.140 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$1.060 (193.43%) $0.699 |
| Date: 2024-04-24 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.331 - 0.391 ( +/- 8.30%) |
| ATR Model: 14 days |
Forecast:
16:00 - $0.364
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.364
Forecast 2: 16:00 - $0.364
Forecast 3: 16:00 - $0.364
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.361 (-0.63% ) |
| Volume | 0.0663 mill |
| Avg. Vol. | 0.213 mill |
| % of Avg. Vol | 31.16 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For GLMD
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
GLMD
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.
Last 10 Buy Signals
Latest Press Releases
2024-04-04 17:06:00 - Press Release
Galmed Pharmaceuticals Ltd. Files Annual Report On Form 20-f For The Fiscal Year Ended December 31, 2023
Tel aviv, israel , april 4, 2024 /prnewswire/ -- galmed pharmaceuticals ltd. (nasdaq: glmd) ("galmed" or the "company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, today announced that it has filed its annual report on form 20-f for the fiscal year ended december 31, 2023, with the u.s. securities and exchange commission (the "sec").
2024-03-15 09:00:00 - Press Release
Galmed Announces Grant Of New Patent For The Combination Of Aramchol With Resmetirom (mgl-3196, Rezdiffra) For The Treatment Of Nash And Liver Fibrosis
Tel aviv, israel , march 15, 2024 /prnewswire/ -- galmed pharmaceuticals ltd. (nasdaq: glmd) ("galmed" or the "company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases announced today the grant of a european patent related to the use of a combination of aramchol and resmetirom (mgl-3196, rezdiffra) for the treatment of nash/mash and liver fibrosis.
2023-11-20 16:32:00 - Press Release
Galmed Announces A Delay In The Initiation Of Its Primary Sclerosing Cholangitis (psc) Phase 2a Study
Tel aviv, israel , nov. 20, 2023 /prnewswire/ -- galmed pharmaceuticals ltd. (nasdaq: glmd) ("galmed" or the "company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, announced today a delay of at least 6 months in the initiation of its primary sclerosing cholangitis (psc) ph 2a study.
2023-09-26 08:30:00 - Press Release
Galmed Announces Allowance Of New Patent For Aramchol For The Treatment Of Pulmonary And Dermal Fibrosis
Tel aviv, israel , sept. 26, 2023 /prnewswire/ -- galmed pharmaceuticals ltd.
2023-09-22 16:05:00 - Press Release
Galmed Pharmaceuticals Announces Receipt Of Nasdaq Minimum Bid Price Notification
Tel aviv, israel , sept. 22, 2023 /prnewswire/ —galmed pharmaceuticals ltd.
Latest News
2024-04-10 06:30:00 - InvestorPlace
Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for April 2024
Now could be a great time for investors to consider stacking up on penny stocks. These companies often have significant growth potential.
2023-07-13 09:26:43 - InvestorPlace
Why Is Galmed Pharmaceuticals (GLMD) Stock Moving Today?
Galmed Pharmaceuticals (NASDAQ: GLMD ) stock is on the move Thursday after the company priced a public offering of its shares. Galmed Pharmaceuticals intends to offer up 6,578,947 shares of GLMD stock at a price of $2.28 per share.
2023-05-05 08:57:37 - InvestorPlace
Why Is Galmed Pharmaceuticals (GLMD) Stock Up 37% Today?
Galmed Pharmaceuticals (NASDAQ: GLMD ) stock is gaining on Friday after the company announced an investment agreement with OnKai . That agreement has Galmed Pharmaceuticals making a $1.5 million equity investment in OnKai.
2022-09-14 13:29:10 - Zacks Investment Research
Galmed Pharmaceuticals (GLMD) Moves to Buy: Rationale Behind the Upgrade
Galmed Pharmaceuticals (GLMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2022-05-02 13:56:04 - Seeking Alpha
Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q4 2021 Results - Earnings Call Transcript
Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD ) Q4 2021 Earnings Conference Call May 2, 2022 8:30 AM ET Company Participants Allen Baharaff - President and CEO Yohai Stenzler - Chief Accounting Officer Conference Call Participants Steven Seedhouse - Raymond James Kristen Kluska - Cantor Fitzgerald Naz Rahman - Maxim Group Operator Good day and welcome to the Galmed Conference Call to discuss Financial Results for the Fourth Quarter and Year-end 2021.
2021-11-08 15:24:06 - Seeking Alpha
Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q3 2021 Results - Earnings Call Transcript
Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q3 2021 Results - Earnings Call Transcript
2021-08-19 11:49:50 - Benzinga
Galmed's Anti-Inflammatory Compound Shows Encouraging Preclinical Action
Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) has announced the data publication for its preclinical compound, Amilo-5MER, in the Journal of Autoimmunity. Amilo-5MER is a five amino acid in a specific sequence originally isolated from synovial fluid of rheumatoid arthritis patients.
2021-08-19 08:00:00 - PRNewsWire
Galmed Pharmaceuticals Announces Publication in "The Journal of Autoimmunity" for its IND ready, Amilo-5MER, a specific anti-inflammatory compound
TEL AVIV, Israel, Aug. 19, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today the publication in The Journal of Autoimmunity for its IND ready compound, Amilo-5MER entitled: "MTADV 5-MER peptide suppresses chronic inflammations as well as autoimmune pathologies and unveils a new potential target-Serum Amyloid A.
2021-08-09 11:00:53 - Seeking Alpha
Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q2 2021 Results - Earnings Call Transcript
Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q2 2021 Results - Earnings Call Transcript
2021-08-02 08:29:33 - Pulse2
GLMD Stock Increases Over 4% Pre-Market: Why It Happened
The stock price of Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) increased by over 4% pre-market. This is why it happened.